Tuesday, April 12, 2011
Vivus Inc., of Mountain View, Calif., said detailed results from the 56-week CONQUER study published in The Lancet showed that obesity candidate Qnexa (phentermine/topiramate) produced an average weight loss of 28 pounds and 22 pounds with the top and mid doses, respectively, compared to four pounds in the placebo group. Data also showed a systolic blood pressure reductions of 4.7 mm Hg (p = 0.0008) and 5.6 mm Hg (p < 0.0001), respectively, vs. 2.4 mm Hg in the placebo group. And Qnexa improved HDL cholesterol by 5.2 percent (p < 0.0001) and 6.8 percent (p < 0.0001), respectively, compared to 1.2 percent for placebo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.